| Revision as of 17:22, 8 September 2011 editAztecWarrior28 (talk | contribs)Extended confirmed users2,379 edits starting mab page |
Latest revision as of 10:45, 19 November 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers174,119 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper |
| (17 intermediate revisions by 12 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
|
| verifiedrevid = 457124199 |
|
| type = mab |
|
| type = mab |
|
| image = |
|
| image = |
| Line 12: |
Line 16: |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category= |
|
| pregnancy_category= |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
| Line 23: |
Line 27: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
|
| CAS_number_Ref = {{cascite|changed|CAS}} |
|
| CAS_number = 912628-39-8 |
|
| CAS_number = 1062149-33-0 |
|
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
|
| UNII = 914910XFBB |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = |
|
| PubChem = |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
|
| C=6334 | H=9792 | N=1700 | O=2000 | S=42 |
|
| DrugBank = |
|
|
| C=6334 | H=9792 | N=1700 | O=2000 | S=42 |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| molecular_weight = 143.1 kDa |
|
|
|
| ChemSpiderID = none |
|
|
| KEGG = D09896 |
|
}} |
|
}} |
|
|
|
|
|
|
'''Enavatuzumab''' is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the ].<ref name="pmid29054986">{{cite journal | vauthors = Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D | display-authors = 6 | title = Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors | journal = Molecular Cancer Therapeutics | volume = 17 | issue = 1 | pages = 215–221 | date = January 2018 | pmid = 29054986 | pmc = 5752572 | doi = 10.1158/1535-7163.MCT-17-0330 }}</ref> |
|
'''Enavatuzumab''' is a humanized monoclonal antibody used in the treatment of solid tumors. |
|
|
|
|
|
|
Enavatuzumab was developed by Facet Biotech Corp.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=]|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref> |
|
Enavatuzumab was developed by Facet Biotech Corp.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=]|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref> |
|
|
|
|
|
== References == |
|
==References== |
|
|
{{reflist|30em}} |
|
|
|
|
⚫ |
{{Monoclonals for tumors}} |
|
|
{{Cytokine receptor modulators}} |
|
|
|
|
|
] |
|
|
|
|
|
<references/> |
|
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
|
|
{{antineoplastic-drug-stub}} |
| ⚫ |
{{monoclonals for tumors}} |
|